Andre C. Schuh

机构：University of Toronto, Princess Margaret Cancer Centre · ORCID：0000-0003-2869-852X

发表论文 363 篇 · 总被引 18565 次 · h-index 47

代表论文

• Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) (2024 · Journal of Clinical Oncology · 被引 232)
• Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine (2024 · Blood · 被引 150)
• Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study (2025 · Blood · 被引 68)
• Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1 -mutated AML (2025 · Blood Advances · 被引 27)
• Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial (2025 · The Lancet Haematology · 被引 25)
• Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations (2025 · Blood · 被引 12)